Teladoc Health (TDOC) EBITDA (2014 - 2026)

Teladoc Health has disclosed EBITDA across 13 years of filings, most recently posting -$37.1 million for Q2 2026.

• In Q2 2026, EBITDA rose 31.8% year-over-year to -$37.1 million; the TTM figure through Jun 2026 stood at -$186.8 million (up 30.19% YoY), while the FY2025 annual figure was -$263.0 million, up 74.24% from the prior year.
• EBITDA came in at -$37.1 million for Q2 2026 at Teladoc Health, up from -$61.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $54.5 million in Q1 2022 to a low of -$3.8 billion in Q4 2022.
• Average EBITDA over 5 years is -$468.4 million, with a median of -$58.1 million recorded in 2025.
• The largest YoY upside for EBITDA was 164.36% in 2022 against a maximum downside of 9109.86% in 2022.
• Over 5 years, EBITDA stood at -$3.8 billion in 2022, then surged by 99.08% to -$35.1 million in 2023, then plunged by 37.44% to -$48.2 million in 2024, then rose by 25.34% to -$36.0 million in 2025, then fell by 3.04% to -$37.1 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$37.1 million in Q2 2026, -$61.8 million in Q1 2026, and -$36.0 million in Q4 2025.